NO20010686D0 - Hydroksypipecolathydroksaminsyrederivater som MMP inhibitorer - Google Patents

Hydroksypipecolathydroksaminsyrederivater som MMP inhibitorer

Info

Publication number: NO20010686D0
Authority: NO; Norway
Prior art keywords: hydroxypipecolate; acid derivatives; hydroxamic acid; mmp inhibitors; mmp
Prior art date: 1998-08-12

Application number

NO20010686A

Other languages

English (en)

Other versions

NO20010686L (no

Inventor

Kim Francis Mcclure

Mark Carl Noe

Michael Anthony Letavic

Louis Stanley Chupak

Original Assignee

Pfizer Prod Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-08-12

Filing date

2001-02-09

Publication date

2001-02-09

2001-02-09 Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc

2001-02-09 Publication of NO20010686D0 publication Critical patent/NO20010686D0/no

2001-04-09 Publication of NO20010686L publication Critical patent/NO20010686L/no

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
- C07D211/96—Sulfur atom
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
- C07D213/30—Oxygen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
- C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
- C07D317/54—Radicals substituted by oxygen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/28—Halogen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Physical Education & Sports Medicine (AREA)
Pulmonology (AREA)
Neurology (AREA)
Orthopedic Medicine & Surgery (AREA)
Rheumatology (AREA)
Neurosurgery (AREA)
Diabetes (AREA)
Biomedical Technology (AREA)
Virology (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Hematology (AREA)
Ophthalmology & Optometry (AREA)
Tropical Medicine & Parasitology (AREA)
AIDS & HIV (AREA)
Cardiology (AREA)
Hospice & Palliative Care (AREA)
Obesity (AREA)
Heart & Thoracic Surgery (AREA)
Psychiatry (AREA)
Molecular Biology (AREA)
Emergency Medicine (AREA)
Endocrinology (AREA)
Transplantation (AREA)

NO20010686A 1998-08-12 2001-02-09 Hydroksypipecolathydroksyaminsyrederivater som MMP inhibitorer NO20010686L (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US9623298P	1998-08-12	1998-08-12
PCT/IB1999/001388 WO2000009485A1 (en)	1998-08-12	1999-08-05	Hydroxy pipecolate hydroxamic acid derivatives as mmp inhibitors

Publications (2)

Publication Number	Publication Date
NO20010686D0 true NO20010686D0 (no)	2001-02-09
NO20010686L NO20010686L (no)	2001-04-09

Family

ID=22256467

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20010686A NO20010686L (no)	1998-08-12	2001-02-09	Hydroksypipecolathydroksyaminsyrederivater som MMP inhibitorer

Country Status (43)

Country	Link
US (2)	US6329397B1 (no)
EP (1)	EP1104403B1 (no)
JP (1)	JP2002522528A (no)
KR (1)	KR20010085374A (no)
CN (1)	CN1316995A (no)
AP (1)	AP2001002070A0 (no)
AR (1)	AR019241A1 (no)
AT (1)	ATE325791T1 (no)
AU (1)	AU766366B2 (no)
BG (1)	BG105323A (no)
BR (1)	BR9912909A (no)
CA (1)	CA2340202C (no)
CZ (1)	CZ2001484A3 (no)
DE (1)	DE69931266T2 (no)
DZ (1)	DZ2870A1 (no)
EA (1)	EA200100126A1 (no)
EE (1)	EE200100086A (no)
ES (1)	ES2263279T3 (no)
GE (1)	GEP20033117B (no)
GT (1)	GT199900131A (no)
HK (1)	HK1040242A1 (no)
HN (1)	HN1999000131A (no)
HR (1)	HRP20010098A2 (no)
HU (1)	HUP0103452A3 (no)
ID (1)	ID27840A (no)
IL (1)	IL141030A0 (no)
IS (1)	IS5813A (no)
MA (1)	MA26675A1 (no)
NO (1)	NO20010686L (no)
NZ (1)	NZ509296A (no)
OA (1)	OA11594A (no)
PA (1)	PA8479201A1 (no)
PE (1)	PE20000951A1 (no)
PL (1)	PL346041A1 (no)
SK (1)	SK1872001A3 (no)
SV (1)	SV1999000123A (no)
TN (1)	TNSN99156A1 (no)
TR (1)	TR200100474T2 (no)
UA (1)	UA59453C2 (no)
UY (1)	UY25993A1 (no)
WO (1)	WO2000009485A1 (no)
YU (1)	YU5201A (no)
ZA (1)	ZA200101042B (no)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6846799B1 (en)	1998-08-18	2005-01-25	The Regents Of The University Of California	Preventing airway mucus production by administration of EGF-R antagonists
US7354894B2 (en)	1998-08-18	2008-04-08	The Regents Of The University Of California	Preventing airway mucus production by administration of EGF-R antagonists
EP1124555A4 (en) *	1998-08-31	2003-03-12	Merck & Co Inc	METHOD FOR TREATING NEURODEGENERATIVE DISEASES
US6509337B1 (en) *	1998-09-17	2003-01-21	Pfizer Inc.	Arylsulfonyl Hydroxamic Acid derivatives as MMP and TNF inhibitors
US6833373B1 (en)	1998-12-23	2004-12-21	G.D. Searle & Co.	Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
US6858598B1 (en)	1998-12-23	2005-02-22	G. D. Searle & Co.	Method of using a matrix metalloproteinase inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
EP1081137A1 (en)	1999-08-12	2001-03-07	Pfizer Products Inc.	Selective inhibitors of aggrecanase in osteoarthritis treatment
EP1138680A1 (en) *	2000-03-29	2001-10-04	Pfizer Products Inc.	Gem substituted sulfonyl hydroxamic acids as MMP inhibitors
JP2001322977A (ja) *	2000-05-12	2001-11-20	Kotobuki Seiyaku Kk	ピペコリン酸誘導体及びその製造方法並びにこれを含有する医薬組成物
JP2002105073A (ja) *	2000-09-27	2002-04-10	Shionogi & Co Ltd	新規マトリックスメタロプロテアーゼ阻害剤
DOP2002000333A (es)	2001-02-14	2002-09-30	Warner Lambert Co	Derivados de acido isoftalico como inhibidores de metaloproteinasas de la matriz
DOP2002000328A (es)	2001-02-14	2003-08-30	Warner Lambert Co	Pirimidinas inhibidoras de metaloproteinasas de matriz
PA8539501A1 (es)	2001-02-14	2002-09-30	Warner Lambert Co	Compuestos triazolo como inhibidores de mmp
DOP2002000332A (es)	2001-02-14	2002-08-30	Warner Lambert Co	Inhibidores de piridina de metaloproteinasas de la matriz
US6924276B2 (en)	2001-09-10	2005-08-02	Warner-Lambert Company	Diacid-substituted heteroaryl derivatives as matrix metalloproteinase inhibitors
CA2462442A1 (en)	2001-10-12	2003-04-24	Warner-Lambert Company Llc	Alkyne matrix metalloproteinase inhibitors
US6962922B2 (en)	2001-10-12	2005-11-08	Warner-Lambert Company Llc	Alkynylated quinazoline compounds
PE20030701A1 (es)	2001-12-20	2003-08-21	Schering Corp	Compuestos para el tratamiento de trastornos inflamatorios
US6894057B2 (en)	2002-03-08	2005-05-17	Warner-Lambert Company	Oxo-azabicyclic compounds
CN1325473C (zh) *	2002-06-26	2007-07-11	卡尔那生物科学株式会社	吖糖衍生物和以其为有效成分的药剂
EP1525030A1 (en) *	2002-07-17	2005-04-27	Warner-Lambert Company LLC	Combination of an allosteric alkyne inhibitor of matrix metalloproteinase-13 with a selective inhibitor of cyclooxygenase-2 that is not celecoxib or valdecoxib
AU2003249505A1 (en) *	2002-07-17	2004-02-02	Warner-Lambert Company Llc	Combination of an allosteric alkyne inhibitor of matrix metalloproteinase-13 with celecoxib or valdecoxib
AU2003250470A1 (en)	2002-08-13	2004-02-25	Warner-Lambert Company Llc	Pyrimidinone fused bicyclic metalloproteinase inhibitors
PA8578101A1 (es)	2002-08-13	2004-05-07	Warner Lambert Co	Derivados de heterobiarilo como inhibidores de metaloproteinasa de la matriz
EP1553949B1 (en)	2002-08-13	2007-04-18	Warner-Lambert Company LLC	Pyrimidine-2,4-dione derivatives as matrix metalloproteinase inhibitors
AU2003249540A1 (en)	2002-08-13	2004-02-25	Warner-Lambert Company Llc	Fused bicyclic metalloproteinase inhibitors
WO2004014866A1 (en)	2002-08-13	2004-02-19	Warner-Lambert Company Llc	Azaisoquinoline derivatives as matrix metalloproteinase inhibitors
WO2004014378A1 (en)	2002-08-13	2004-02-19	Warner-Lambert Company Llc	3-isoquinolinone derivatives as matrix metalloproteinase inhiitors
WO2004014892A1 (en)	2002-08-13	2004-02-19	Warner-Lambert Company Llc	Monocyclic derivatives as matrix metalloproteinase inhibitors
CA2497658A1 (en)	2002-08-13	2004-02-19	Warner-Lambert Company Llc	Chromone derivatives as matrix metalloproteinase inhibitors
AU2003249477A1 (en)	2002-08-13	2004-02-25	Warner-Lambert Company Llc	Heterobicylcic metalloproteinase inhibitors
AU2003253186A1 (en)	2002-08-13	2004-02-25	Warner-Lambert Company Llc	Fused tetrahydropyridine derivatives as matrix metalloproteinase inhibitors
CA2600954A1 (en) *	2005-03-22	2006-12-14	Innodia Inc.	Compounds and compositions for use in the prevention and treatment of obesity and related syndromes
NZ587799A (en)	2008-03-25	2012-06-29	Affectis Pharmaceuticals Ag	Novel p2x7r antagonists and their use
WO2010118921A1 (en)	2009-04-14	2010-10-21	Affectis Pharmaceuticals Ag	Novel p2x7r antagonists and their use
WO2012110190A1 (en)	2011-02-17	2012-08-23	Affectis Pharmaceuticals Ag	Novel p2x7r antagonists and their use
WO2012163456A1 (en)	2011-05-27	2012-12-06	Affectis Pharmaceuticals Ag	Novel p2x7r antagonists and their use
WO2012163792A1 (en)	2011-05-27	2012-12-06	Affectis Pharmaceuticals Ag	Novel p2x7r antagonists and their use
DE202016007195U1 (de)	2016-11-16	2017-11-17	Bernhard Kohler	Strombegrenzende Schalteinrichtung
WO2020160140A1 (en) *	2019-01-29	2020-08-06	Darsha Llc	Compositions and methods for treating pulmonary disease with matrix metalloproteinase inhibitors

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2153031T4 (es) *	1995-04-20	2001-05-16	Pfizer	Derivados del acido arilsulfonil hidroxamico como inhibidores de mmp y tnf.
BR9611929A (pt) *	1995-12-08	1999-05-18	Agouron Pharma	Inibidores de metaloproteinase composições farmacéuticas contendo os mesmos e seus usos farmacéuticos e métodos e intermediários úteis
SK25099A3 (en) *	1996-08-28	2000-02-14	Procter & Gamble	Substituted cyclic amine metalloprotease inhibitors
WO1998033768A1 (en) *	1997-02-03	1998-08-06	Pfizer Products Inc.	Arylsulfonylamino hydroxamic acid derivatives
BR9807678A (pt) *	1997-02-11	2000-02-15	Pfizer	Derivados de ácidos arilsulfonil-hidroxâmicos
WO1998050348A1 (en) *	1997-05-09	1998-11-12	Agouron Pharmaceuticals, Inc.	Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses

1999
- 1999-05-08 UA UA2001010473A patent/UA59453C2/uk unknown
- 1999-07-30 PA PA19998479201A patent/PA8479201A1/es unknown
- 1999-08-03 YU YU5201A patent/YU5201A/sh unknown
- 1999-08-05 DE DE69931266T patent/DE69931266T2/de not_active Expired - Fee Related
- 1999-08-05 BR BR9912909-4A patent/BR9912909A/pt not_active Application Discontinuation
- 1999-08-05 EA EA200100126A patent/EA200100126A1/ru unknown
- 1999-08-05 EE EEP200100086A patent/EE200100086A/xx unknown
- 1999-08-05 ID IDW20010327A patent/ID27840A/id unknown
- 1999-08-05 WO PCT/IB1999/001388 patent/WO2000009485A1/en active IP Right Grant
- 1999-08-05 EP EP99933076A patent/EP1104403B1/en not_active Expired - Lifetime
- 1999-08-05 OA OA1200100035A patent/OA11594A/en unknown
- 1999-08-05 HU HU0103452A patent/HUP0103452A3/hu unknown
- 1999-08-05 SK SK187-2001A patent/SK1872001A3/sk unknown
- 1999-08-05 AT AT99933076T patent/ATE325791T1/de not_active IP Right Cessation
- 1999-08-05 ES ES99933076T patent/ES2263279T3/es not_active Expired - Lifetime
- 1999-08-05 NZ NZ509296A patent/NZ509296A/en unknown
- 1999-08-05 JP JP2000564939A patent/JP2002522528A/ja not_active Ceased
- 1999-08-05 TR TR2001/00474T patent/TR200100474T2/xx unknown
- 1999-08-05 CN CN99810697A patent/CN1316995A/zh active Pending
- 1999-08-05 AP APAP/P/2001/002070A patent/AP2001002070A0/en unknown
- 1999-08-05 CZ CZ2001484A patent/CZ2001484A3/cs unknown
- 1999-08-05 KR KR1020017001847A patent/KR20010085374A/ko not_active Application Discontinuation
- 1999-08-05 AU AU49247/99A patent/AU766366B2/en not_active Ceased
- 1999-08-05 GE GEAP19995744A patent/GEP20033117B/en unknown
- 1999-08-05 IL IL14103099A patent/IL141030A0/xx unknown
- 1999-08-05 CA CA002340202A patent/CA2340202C/en not_active Expired - Fee Related
- 1999-08-05 PL PL99346041A patent/PL346041A1/xx not_active Application Discontinuation
- 1999-08-09 HN HN1999000131A patent/HN1999000131A/es unknown
- 1999-08-10 AR ARP990103994A patent/AR019241A1/es not_active Application Discontinuation
- 1999-08-10 PE PE1999000807A patent/PE20000951A1/es not_active Application Discontinuation
- 1999-08-11 DZ DZ990170A patent/DZ2870A1/xx active
- 1999-08-11 TN TNTNSN99156A patent/TNSN99156A1/fr unknown
- 1999-08-11 SV SV1999000123A patent/SV1999000123A/es not_active Application Discontinuation
- 1999-08-11 MA MA25730A patent/MA26675A1/fr unknown
- 1999-08-12 GT GT199900131A patent/GT199900131A/es unknown
- 1999-08-12 US US09/372,946 patent/US6329397B1/en not_active Expired - Fee Related
2000
- 2000-01-28 UY UY25993A patent/UY25993A1/es unknown
2001
- 2001-01-16 IS IS5813A patent/IS5813A/is unknown
- 2001-02-07 ZA ZA200101042A patent/ZA200101042B/en unknown
- 2001-02-08 HR HR20010098A patent/HRP20010098A2/hr not_active Application Discontinuation
- 2001-02-09 NO NO20010686A patent/NO20010686L/no not_active Application Discontinuation
- 2001-03-09 BG BG105323A patent/BG105323A/xx unknown
- 2001-12-03 US US10/008,943 patent/US20030008901A1/en not_active Abandoned
2002
- 2002-02-26 HK HK02101437.7A patent/HK1040242A1/zh unknown

Also Published As

Publication number	Publication date
BG105323A (en)	2001-10-31
OA11594A (en)	2004-07-11
AP2001002070A0 (en)	2001-03-31
DE69931266D1 (en)	2006-06-14
NZ509296A (en)	2003-10-31
AU766366B2 (en)	2003-10-16
SV1999000123A (es)	2000-07-06
ID27840A (id)	2001-04-26
CZ2001484A3 (cs)	2002-05-15
EP1104403B1 (en)	2006-05-10
IS5813A (is)	2001-01-16
EE200100086A (et)	2002-08-15
SK1872001A3 (en)	2002-08-06
HRP20010098A2 (en)	2002-02-28
JP2002522528A (ja)	2002-07-23
UY25993A1 (es)	2000-03-31
YU5201A (sh)	2003-07-07
BR9912909A (pt)	2001-05-08
GEP20033117B (en)	2003-11-25
ATE325791T1 (de)	2006-06-15
GT199900131A (es)	2001-02-02
HN1999000131A (es)	2000-03-24
DZ2870A1 (fr)	2003-12-15
HK1040242A1 (zh)	2002-05-31
PA8479201A1 (es)	2000-09-29
IL141030A0 (en)	2002-02-10
WO2000009485A1 (en)	2000-02-24
AU4924799A (en)	2000-03-06
EP1104403A1 (en)	2001-06-06
AR019241A1 (es)	2001-12-26
PE20000951A1 (es)	2000-09-27
TNSN99156A1 (fr)	2005-11-10
PL346041A1 (en)	2002-01-14
KR20010085374A (ko)	2001-09-07
TR200100474T2 (tr)	2001-06-21
ES2263279T3 (es)	2006-12-01
US20030008901A1 (en)	2003-01-09
DE69931266T2 (de)	2007-02-15
ZA200101042B (en)	2002-10-07
HUP0103452A2 (hu)	2002-04-29
EA200100126A1 (ru)	2001-08-27
HUP0103452A3 (en)	2002-10-28
UA59453C2 (uk)	2003-09-15
US6329397B1 (en)	2001-12-11
CA2340202C (en)	2006-02-07
CN1316995A (zh)	2001-10-10
CA2340202A1 (en)	2000-02-24
NO20010686L (no)	2001-04-09
MA26675A1 (fr)	2004-12-20

Publication	Publication Date	Title
NO20010686D0 (no)	2001-02-09	Hydroksypipecolathydroksaminsyrederivater som MMP inhibitorer
DK1036062T3 (da)	2004-04-05	Hydroxamsyrederivater som matrix metalloprotease (MMP) inhibitorer
DK2253620T3 (da)	2014-03-31	Substituerede 3-cyanoquinoliner som protein-tyrosinkinase-inhibitorer
NO20030867L (no)	2003-02-25	Hydroksamderivater anvendelig som deacetylaseinhibitorer
DK1244647T3 (da)	2006-09-25	Quinzolinderivater som VIGF-inhibitorer
ATE245142T1 (de)	2003-08-15	No-synthase inhibitoren
DK0821671T3 (da)	2001-04-23	Arylsulfonylhydroxamsyrederivater som MMP- og TNF-inhibitorer
NO20015543D0 (no)	2001-11-13	Aromatisk sulfonhydroksaminsyre-metalloproteaseinhibitor
ATE245158T1 (de)	2003-08-15	Bicyclische hydroxamsäurederivate
NO20031450D0 (no)	2003-03-28	Fumarsyrederivater som NF-kappa B inhibitorer
NO20002469D0 (no)	2000-05-12	Aromatisk sulfonhydroksamsyre-metalloproteaseinhibitor
DK1097127T3 (da)	2003-06-10	Diacylhydrazinderivater som integrininhibitorer
NO994103D0 (no)	1999-08-25	Reverse hydroksamatderivater som metallproteaseinhibitorer
AU2594799A (en)	1999-08-30	Novel cyclic sulfonamide derivatives as metalloproteinase inhibitors
DE60043730D1 (de)	2010-03-11	Arylsulfonamid-substituierte hydroxamsäure-derivate
DK1147080T3 (da)	2004-09-27	Alkynylholdige hydroxamsyreforbindelser som TACE-inhibitorer
NO991994L (no)	1999-06-15	Substituerte 4-bifenyl-4-hydroksysm°rsyrederivater som matriksmetalloproteaseinhibitorer
NO20021959D0 (no)	2002-04-25	Tetrahydrotiopyranftalazinon-derivater som PDE4-inhibitorer
DE60009260D1 (de)	2004-04-29	Thiopyranderivate as mmp-inhibitoren
AU2202101A (en)	2001-06-25	Hydroxamic acid derivatives as matrix metalloproteinase (mmp) inhibitors
DK1121349T3 (da)	2004-07-12	Substituerede thiadiazolsulfonamider som interleukin-1-beta-inhibitorer
NO20011654D0 (no)	2001-04-02	Benzamidderivater som trombininhibitorer
AU2001247399A1 (en)	2002-09-24	Heterocyclic hydroxamic acid derivatives as mmp inhibitors
NO965353D0 (no)	1996-12-13	3-amino-2-okso-1-piperidineddiksyrederivater som enzyminhibitorer

Legal Events

Date	Code	Title	Description
2005-05-02	FC2A	Withdrawal, rejection or dismissal of laid open patent application